Ansa Bio's Guarantee Aims to Reshape DNA Synthesis Market

EMERYVILLE, CA – April 29, 2026 – As the synthetic biology world prepares to converge on San Jose for the SynBioBeta 2026 conference, one company is poised to capture the spotlight not just with breakthrough technology, but with a bold business promise: your complex DNA, delivered on time, or it's free. Ansa Biotechnologies, a firm specializing in enzymatic DNA synthesis, is leveraging the industry's premier event to showcase its platform and an unprecedented on-time, complete order shipment guarantee that could fundamentally alter the landscape for researchers in gene therapy, vaccine development, and beyond.

The company's presence at the conference will include several high-profile presentations from its leadership, including CEO Jason T. Gammack. "The SynBioBeta conference is where we engage with one of the most forward-thinking communities shaping the next era of biology, and we are eager to share the latest developments in our push to deliver the most accurate and reliable synthetic DNA,” Gammack stated.

A New Standard of Reliability

For scientists working at the cutting edge of biology, the process of acquiring custom synthetic DNA has long been a source of frustration. While essential for their work, ordering long or complex DNA sequences is often a gamble, fraught with uncertain timelines, failed synthesis attempts, and a lack of transparency from providers. Ansa Biotechnologies is tackling this pain point head-on with its "Ansa On-Time Guarantee."

This guarantee is a stark departure from the industry norm. While competitors may offer guarantees on sequence accuracy or have high on-time delivery rates, Ansa's promise is absolute: if a customer's complete order of clonal DNA up to 50 kilobases (kb) is not shipped on the promised date, the entire order is free. This level of accountability is virtually unheard of in the DNA synthesis market.

The move is a strategic one, designed to build trust and eliminate a critical bottleneck for R&D pipelines. By removing the uncertainty of delivery, the company allows research teams to plan experiments with a degree of confidence previously unattainable. "We believe all scientists should expect to have complete confidence in sequence accuracy and delivery timelines, without trade-offs in sequence length or complexity,” Gammack added.

Breaking the Barriers of Synthesis

Underpinning this bold guarantee is a proprietary enzymatic synthesis technology that circumvents the limitations of traditional chemical methods. For decades, the industry has relied on phosphoramidite chemistry, a process that is notoriously inefficient for producing DNA strands longer than about 150 bases and struggles with complex sequences containing repetitive elements or high GC content. This method also generates hazardous chemical waste.

Ansa's platform uses a novel enzymatic approach based on TdT-dNTP conjugates. This process allows for the direct, rapid, and controlled addition of bases to a growing DNA strand in a mild, aqueous environment. The result is the ability to synthesize extremely long and complex DNA constructs—from 100 base pairs to 50 kb—directly, without the error-prone assembly of smaller fragments.

The impact for researchers has been transformative. Scientists from leading institutions who participated in the company's early access program report successfully obtaining DNA that other major providers had failed to produce. One researcher from a prominent synthetic biology hub noted that Ansa delivered "extremely long and complex constructs we couldn't get anywhere else," adding that without the company's technology, obtaining these vital research tools would not have been possible "so efficiently, affordably, and reliably — or at all!”

Another scientist at a major university reported that complex sequences that were repeatedly rejected by other vendors arrived from Ansa and looked "perfect" upon verification. This capability is proving crucial for developing next-generation cell and gene therapies, which often rely on large and intricate DNA payloads like long poly(A) tails or inverted terminal repeats (ITRs) that are notoriously difficult to synthesize chemically.

Competitive Speed, Price, and Responsibility

While the guarantee and technological prowess are the main headlines, Ansa is also competing on the core metrics of speed and price. The company offers turnaround times as short as 11 business days for its complex, long-read products, with pricing starting at a competitive $0.13 per base pair. While some competitors like Twist Bioscience may offer lower per-base costs for shorter, simpler fragments, Ansa's value proposition is centered on its ability to deliver the "undeliverable": long, complex, and sequence-perfect clonal DNA at a predictable cost and timeline.

This performance is coupled with a strong commitment to responsible innovation. All manufacturing is conducted exclusively in the United States, and the company operates in full compliance with the recently established U.S. Office of Science and Technology Policy (OSTP) Framework for Nucleic Acid Synthesis Screening. This framework, which becomes a condition for receiving U.S. government research funding in 2025, mandates strict customer and sequence screening to mitigate the risk of misuse.

Furthermore, the company's enzymatic process is inherently sustainable. By avoiding the harsh organic chemicals used in traditional synthesis, the platform eliminates the production of toxic waste, presenting a greener alternative for the rapidly growing synthetic biology industry. This commitment to biosecurity and sustainability will be a topic of discussion at SynBioBeta, where Ansa's Scott Fay will participate in a panel on "The New Biosecurity Frontier."

At the upcoming conference, Ansa aims to let its customers do the talking. The company's schedule includes a panel titled "Skip the Assembly, Go Straight to Your Next Breakthrough," moderated by Ansa's Geoff Hamilton and featuring scientists from Gilead Sciences, Hexagon Bio, and Integrated DNA Technologies. This focus on customer experience underscores the company's core message: advanced DNA synthesis is no longer just about what's possible in a lab, but about delivering reliable tools that accelerate discovery for the entire scientific community.